BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report)'s share price reached a new 52-week low on Thursday . The stock traded as low as $52.93 and last traded at $59.43, with a volume of 3582347 shares traded. The stock had previously closed at $55.89.
Wall Street Analyst Weigh In
BMRN has been the topic of a number of recent analyst reports. Citigroup increased their price objective on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Piper Sandler lifted their price target on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research report on Thursday, February 20th. Scotiabank boosted their price objective on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a report on Thursday, February 20th. Bank of America raised their target price on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Finally, StockNews.com raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, April 9th. Seven research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.
Get Our Latest Stock Report on BioMarin Pharmaceutical
BioMarin Pharmaceutical Stock Up 0.3 %
The company's fifty day simple moving average is $67.10 and its 200 day simple moving average is $66.52. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $11.42 billion, a P/E ratio of 27.19, a price-to-earnings-growth ratio of 0.61 and a beta of 0.30.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.54 by $0.18. The business had revenue of $747.31 million during the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. Research analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.
Insider Activity at BioMarin Pharmaceutical
In related news, CAO Erin Burkhart sold 1,295 shares of BioMarin Pharmaceutical stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total transaction of $92,618.40. Following the completion of the transaction, the chief accounting officer now directly owns 16,955 shares of the company's stock, valued at $1,212,621.60. This trade represents a 7.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.85% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On BioMarin Pharmaceutical
Several large investors have recently made changes to their positions in BMRN. Farther Finance Advisors LLC increased its position in BioMarin Pharmaceutical by 95.9% during the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock valued at $29,000 after buying an additional 211 shares in the last quarter. LRI Investments LLC grew its stake in shares of BioMarin Pharmaceutical by 856.9% in the fourth quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 437 shares during the last quarter. TD Private Client Wealth LLC increased its holdings in shares of BioMarin Pharmaceutical by 57.4% during the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 186 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth about $36,000. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in BioMarin Pharmaceutical by 71.2% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 218 shares in the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.
About BioMarin Pharmaceutical
(
Get Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Further Reading
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
